Research article · 2017
Conference abstractPublished 27 Jun 2016
Intellectual property issues in global biosimilar programs
Michalski HÃ?¼ttermann & Partner, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In addition to development, manufacturing and commercial challenges, patent legal issues have a major impact on the success of a global biosimilar program. The multidimensional complexity of the patent landscape relating to a biosimilar candidate is due to the variety of categories of patent rights, encompassing, e.g., compound, process, formulation, indication, dosage and device patents; to the territorial diversity in scope and term of patent protection; to the technical complexity of biopharmaceutical production; and to the rapidly evolving, often controversial case law in this field. All these aspects need to be addressed when it comes to freedom-to-operate analysis and clearance of biosimilar projects, but is also relevant for securing oneâÂ?Â?s own IP position by filing and prosecuting applications on, e.g., improved process, formulation or device features. The talk will discuss challenges and chances along those lines and will give relevant examples. An update will be provided on some recent developments in patent law which will have an impact on future biologics and biosimilars patent landscapes in major markets, such as the Unitary Patent in Europe and the evolving biosimilars legislation in the US.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Oct 2014
The positive role of intellectual property in the creation of cost effective and affordable biosimilars
Conference abstract · 23 Sep 2013
Patents and biosimilars: Ensuring strong intellectual property protection
Conference abstract · 1 Mar 2019
Eurobiosimilars 2019: Interchangeability of biosimilars and intellectual property law - Marek Swierczynski - University of Cardinal Stefan Wyszynski
Conference abstract · 15 May 2017
Intellectual property and regulatory interplay in biosimilars
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Christoph Volpers”

